We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed...
TG Therapeutics, Inc. (TGTX) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to umbralisib, the Company’s investigational dual inhibitor of PI3K-delta and CK1-epsilon, for the treatment of patients with follicular lymphoma (FL). The FL cohort of the UNITY-NHL trial is designed to evaluate the safety and efficacy of umbralisib in patients with FL who have received at least two prior lines of therapy including an anti-CD20 monoclonal antibody and an alkylating agent. In October 2019, the Company announced that the FL cohort met the primary endpoint of overall response rate (ORR), and in January the Company initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for umbralisib as a treatment for patients with previously treated marginal zone lymphoma (MZL) and FL.
NEW YORK, May 14, 2020 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 56th American Society of Clinical Oncology.
TG Therapeutics, Inc. (TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases (“TG Therapeutics”), today announced that it intends to offer and sell 6,000,000 shares of its common stock in an underwritten public offering. TG Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. TG Therapeutics intends to use the net proceeds of the public offering to fund the continued development of ublituximab and umbralisib, the potential in-license, acquisition, development and commercialization of other pharmaceutical products, and for general corporate purposes.
TG Therapeutics, Inc. (TGTX), today announced positive topline results from the global UNITY-CLL Phase 3 trial evaluating the combination of umbralisib plus ublituximab (U2) compared to obinutuzumab plus chlorambucil in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia (CLL). The trial met its primary endpoint at a prespecified interim analysis demonstrating a statistically significant improvement in progression-free survival (PFS) (p<.0001), and will be stopped early for superior efficacy.
NEW YORK, May 11, 2020 -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the first quarter ended March 31, 2020 and recent company developments..
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics, Inc. (TGTX), today announced it has raised gross proceeds of approximately $60 million through its At-the-Market (ATM) facility, $40 million of which came from longtime shareholder, RA Capital Management. The Company sold approximately 3.5 million shares of the Company’s common stock on May 5, 2020, at the then-prevailing market prices. TG Therapeutics intends to use the capital raised through the ATM to fund the ongoing development and commercialization of the Company’s lead assets, ublituximab and umbralisib, as well as for research and development activities of the Company’s pipeline, and for general corporate purposes.
Hedge funds don't get the respect they used to get. Nowadays investors prefer passive funds over actively managed funds. One thing they don't realize is that 100% of the passive funds didn't see the coronavirus recession coming, but a lot of hedge funds did. Even we published an article near the end of February and […]
Q4 2019 TG Therapeutics Inc Earnings Call
Mike Weiss has been the CEO of TG Therapeutics, Inc. (NASDAQ:TGTX) since 2011. First, this article will compare CEO...
NEW YORK, March 09, 2020 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that abstracts featuring ublituximab, the Company’s novel, glycoengineered anti-CD20.
TG Therapeutics, Inc. (TGTX), today announced that Owen A. O’Connor, MD, PhD, has joined the Company as Chief Scientific Officer. Dr. O’Connor brings extensive scientific experience in developing drug candidates in oncology and hematology, and most recently served as a Professor of Medicine and Experimental Therapeutics, the Director of the Center for Lymphoid Malignancies, and Co-Program Director of the Lymphoid Development and Malignancy Program in the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center.
TG Therapeutics, Inc. (TGTX) today announced the publication of results from the multicenter Phase 2 trial evaluating ublituximab, the Company’s investigational, glycoengineered, anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis (RMS), in the Multiple Sclerosis Journal. Anti-CD20 therapy has quickly become a very important treatment option for patients with MS, and we believe our Phase 2 data highlight the potential therapeutic benefits for ublituximab delivered in a convenient one-hour infusion following day 1.
NEW YORK, May 14, 2020 -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases (“the Company”),.
TG Therapeutics, Inc. (TGTX), today announced the appointment of Sagar Lonial, MD, FACP, to the Company’s Board of Directors. Dr. Lonial has extensive experience in multiple myeloma and lymphoma treatment and research, and most recently has focused on developing combinations of novel agents for B-cell malignancies, particularly evaluating combinations that may result in synergistic inhibition of the PI3K/Akt pathway.
NEW YORK, May 15, 2020 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that preclinical data for TG-1701, the Company’s highly selective, BTK inhibitor, has been.
TG Therapeutics (TGTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
NEW YORK, Feb. 28, 2020 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday March 3, 2020 at 8:00 AM ET to discuss results.
NEW YORK, March 03, 2020 -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2019 and recent.